Fibrosis / Lung Diseases
HBM contact: Dr Chandra P. Leo
Company status: private
Galecto develops novel drugs targeting a group of
proteins called galectins (or galactoside-binding lectins). These drugs have
applications in the treatment of fibrosis, inflammation, and other serious
conditions. Galecto's lead asset TD139 is a potent and selective inhalable
inhibitor of galectin-3. TD139 is in advanced development for idiopathic
pulmonary fibrosis (IPF), a chronic, progressive and ultimately deadly lung
disease. Galecto is located in Copenhagen, Denmark.